Intellia Therapeutics secures $400m debt facility with OrbiMed
Intellia Therapeutics has secured a $400 million senior secured term loan facility from healthcare investment firm OrbiMed, providing the Cambridge, Massachusetts-based company with non-dilutive capital as it prepares for a potential US commercial launch of its lead in vivo CRISPR candidate.
The agreement was signed on 4 September 2026. An initial tranche of $75 million was drawn at closing. A further $225 million is available across five additional tranches at Intellia's discretion, contingent on the company achieving specified milestones linked primarily to lonvoguran ziclumeran (lonvo-z), its CRISPR-based therapy for hereditary angioedema (HAE). An additional $100 million sits under a mutual-agreement clause that can be activated during the five-year term.
The deal
Edward Dulac, Intellia's chief financial officer, said the structure preserves shareholder value while giving the company room to execute its commercial strategy. "This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE, advance nexiguran ziclumeran through multiple important milestones in transthyretin amyloidosis and create value through our early pipeline development efforts," he said.
Lonvo-z, formerly designated NTLA-2002, is an in vivo CRISPR/Cas9 gene-editing candidate designed to permanently silence the KLKB1 gene, which encodes kallikrein, a key driver of HAE attacks. It has received regulatory designations across three jurisdictions: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, PRIME designation from the European Medicines Agency, and an Innovation Passport from the MHRA. The company is positioning lonvo-z as a potential first-in-class one-time treatment for HAE, pending approval of its biologics licence application. A US approval and commercial launch are described as near-term milestones.
Intellia's second late-stage programme, nexiguran ziclumeran (nex-z, formerly NTLA-2001), targets transthyretin amyloidosis, a protein-misfolding disease of the heart and peripheral nerves. Progress on nex-z milestones is cited as part of the broader capital deployment rationale, though no specific data readout timeline was given in the announcement.
Market context
The deal reflects a wider shift in how clinical-stage biotechs are managing their balance sheets in a rate-sensitive funding environment. Royalty and debt-based financing from specialist healthcare lenders has grown in prominence as an alternative to equity raises that would dilute existing shareholders, particularly for companies with late-stage assets that can serve as collateral against milestone-linked drawdowns.
In the CRISPR gene-editing space, Intellia competes with a small set of in vivo-focused peers, while also facing indirect competition in the HAE market from established subcutaneous prophylactics and plasma kallikrein inhibitors. A one-time curative approach, if approved, would represent a significant differentiation from chronic dosing regimens, though payers will scrutinise long-term durability data carefully before agreeing reimbursement terms.
TD Cowen acted as financial adviser to Intellia on the transaction. Goodwin Procter provided legal counsel to Intellia; Covington and Burling advised OrbiMed. Full loan terms will be filed with the Securities and Exchange Commission on Form 8-K.